Category: Cosmetic/AestheticSyndicate content

Medical device manufacturers making cosmetic / aesthetic products.

Feds take a closer look at Valeant's hostile bid for Allergan

August 11, 2014 by Arezu Sarvestani

The FTC issued a "Second Request" for more information about Valeant Pharmaceuticals' ongoing attempts to take over Allergan.

Feds take a closer look at Valeant's hostile bid for Allergan

Federal authorities are taking a closer look at Allergan's (NYSE:AGN) ongoing battle to keep unrequited acquirer Valeant Pharmaceuticals at bay.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Report: Valeant's hostile takeover hopes fade as Allergan war continues

August 6, 2014 by Arezu Sarvestani

Allergan uses the occasion of unrequited buyer Valeant Pharmaceuticals' latest financial report to drive home allegations that Valeant isn't being upfront about its business and accounting practices.

Allergan attacks activist investor's latest earnings report

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Ulthera pulls $86M IPO in favor of $600M merger

July 23, 2014 by Arezu Sarvestani

Aesthetics devices maker Ulthera withdraws its $86 million initial public offering after agreeing to an acquisition by Merz that's valued at up to $600 million.

Ulthera pulls IPO in favor of merger

Arizona device maker Ulthera is ditching its planned initial public offering in favor of a $600 million merger with larger aesthetics company Merz Inc., according to an SEC filing.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Allergan cuts 1,500 jobs, faces SEC complaint

July 21, 2014 by Arezu Sarvestani

Botox-maker Allergan announces restructuring measures that will cut 13% of its global workforce as the company sinks deeper into a months-long battle against activist investors and attempts at a takeover.

Updated July 21, 2014, at 12:40 p.m. EST with additional information on Allergan's earnings.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

A countdown to failure for Valeant's hostile $53B Allergan takeover

July 18, 2014 by Arezu Sarvestani

Activist investor Bill Ackman urges shareholders to take action before time runs out on Valeant Pharmaceuticals' hostile $53 billion bid to acquire Allergan.

A countdown to failure for Valeant's hostile $53B Allergan takeover

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Report: Another activist investor pressures Allergan to sell

June 27, 2014 by Arezu Sarvestani

Another hedge fund buys a massive stake in Botox-maker Allergan, throwing its support behind Valeant Pharmaceuticals' unrequited acquisition bid, according to a report.

Report: Another activist investor pressures Allergan to sell

Another player entered the arena in the running saga over Allergan (NYSE:AGN) as hedge fund Paulson & Co bought up a huge chunk of the Botox-maker's shares, according to Reuters.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Valeant goes hostile in bid for Allergan

June 18, 2014 by Arezu Sarvestani

Valeant Pharmaceuticals makes its promised hostile play in a $53 billion attempt to take over Botox-maker Allergan.

Valeant goes hostile in bid for Allergan

Valeant Pharmaceuticals is preparing to officially launch its long-promised hostile takeover bid for Allergan (NYSE:AGN), aiming to solicit support from Allergan shareholders to host a special meeting outside of the company's control.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp